Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

NCT04834986 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma

Interventions

DRUG: Tislelizumab combined with Lenvatinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital